Sramel, Peter
19  results:
Search for persons X
?
2

Novel rhodanine based inhibitors of aldose reductase of non..:

Kratky, Martin ; Sramel, Peter ; Bodo, Pavol...
European Journal of Medicinal Chemistry.  246 (2023)  - p. 114922 , 2023
 
?
6

Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleto..:

Murár, Miroslav ; Dobiaš, Juraj ; Šramel, Peter...
European Journal of Medicinal Chemistry.  126 (2017)  - p. 754-761 , 2017
 
?
7

Development of Novel Oxotriazinoindole Inhibitors of Aldose..:

Hlaváč, Matúš ; Kováčiková, Lucia ; Prnová, Marta...
info:eu-repo/semantics/altIdentifier/doi/10.1021/acs.jmedchem.9b01747.  , 2020
 
?
 
?
13

Quinoides and VEGFR2 TKIs influence the fate of hepatocellu..:

Kahraman, Deniz Cansen ; Hanquet, Gilles ; Jeanmart, Loic...
Kahraman D. C. , Hanquet G., Jeanmart L., Lanners S., Sramel P., Bohac A., Cetin-Atalay R., "Quinoides and VEGFR2 TKIs influence the fate of hepatocellular carcinoma and its cancer stem cells.", MedChemComm, cilt.8, ss.81-87, 2016.  , 2016
 
?
14

Quinoides and VEGFR2 TKIs influence the fate of hepatocellu..:

Kahraman, Deniz Cansen ; Hanquet, Gilles ; Jeanmart, Loic...
Kahraman D. C. , Hanquet G., Jeanmart L., Lanners S., Sramel P., Bohac A., Cetin-Atalay R., "Quinoides and VEGFR2 TKIs influence the fate of hepatocellular carcinoma and its cancer stem cells.", MedChemComm, cilt.8, ss.81-87, 2016.  , 2016
 
1-15